ClinicalTrials.gg
RecruitingNCT07168161Updated Aug 13, 2026

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

A Phase 3 interventional study of BDB-001 injection and Cyclophosphamide in ANCA Associated Vasculitis (AAV), sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Recruiting at 65 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China — 42 open to participants now, 46 under way, 1 of them phase 3. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China.

Planned enrollment
Largest of 52
300 · median 18
Started
2025
with 20 others
Phase 3
Only one
of the 57
Primary completion
2027-04
later than 21 of 45 live
Registered
41st of 57
by date
Lead sponsor
2 of 57
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Among the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China, this one has the largest planned enrollment of the 52 interventional ones that give a count, is one of 21 that started in 2025, is the only one in phase 3, reaches primary completion later than 21 of the 45 other live ones, and was the 41st registered.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

158 studies on the registry are indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 76 are open to participants now.

Browse Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies →

Open to participants now

42 of the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies recruiting now, 21 (38%) set no upper age limit and 28 (50%) stop at 75 or younger; 9 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China, or all of them as a file.
02

Study summary

The primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab

03

Conditions studied

  • ANCA Associated Vasculitis (AAV)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old≤Age≤75 years old, male or female;
  2. Diagnosis of granulomatosis with polyangiitis(GPA) or microscopic polyangiitis(MPA);
  3. Newly diagnosed or GPA or MPA that requires treatment with a full starting dose of prednisone plus cyclophosphamide/azathioprine or rituximab;
  4. Positive test for anti-proteinase 3(PR3) or anti-myeloperoxidase (MPO);
  5. Estimated ≥15 mL/minute/1.73 m\^2;
  6. At least 1 major item, or at least 3 non-major items, or at least the 2 renal items on BVAS;

Exclusion criteria

Exclusion Criteria:

  1. Active tuberculosis infection;
  2. alveolar hemorrhage requiring pulmonary ventilation support;
  3. History of any of any organ system within 5 years prior to the first dose, except for basal cell carcinoma of the skin or carcinoma in situ (e.g., cervical or breast carcinoma in situ) that has been completely resected and shows no evidence of local recurrence or .
  4. Any other known multi-system disease including eosinophilic granulomatosis with polyangiitis (Churg-Strauss), systemic lupus erythematosus, IgA vasculitis (Henoch-Schönlein), rheumatoid vasculitis,anti-glomerular basement membrane disease, or cryoglobulinemic vasculitis;
  5. positive,or HBcAb positive and HBV-DNA positive;
  6. Received CYC within 3 months before the first administration or Received rituximab(RTX) or other B-cell antibody within 12 months before the first administration;
  7. Received shock therapy within 4 weeks before the first administration;
  8. Received an oral daily dose of a GC of > 10 mg prednisone-equivalent for more than 6 weeks continuously before the first administration;
  9. Received a anti-tumor necrosis factor and other biological agents treatment within 12 weeks before the first administration;
  10. Received Continuous dialysis treatment for 12 weeks or more before the first administration; Received Dialysis within 1 week before the first administration;
  11. Received intravenous immunoglobulin (Ig) or plasma exchange within 4 weeks before the first administration;
  12. Pregnant or lactating.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    BDB-001 injection group

    BDB-001 injection plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.

    Drug: BDB-001 injection · Drug: Cyclophosphamide · Drug: Rituximab · Drug: Azathioprine

  • Active comparator
    Prednisone group

    BDB-001 injection-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.

    Drug: Cyclophosphamide · Drug: Rituximab · Drug: Azathioprine · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of patients achieving disease remission assessed by Birmingham Vasculitis Activity Score (BVAS)

    Time frame: Week 24

Secondary outcomes

  1. The proportion of patients achieving disease sustained remission assessed by Birmingham Vasculitis Activity Score (BVAS)

    Time frame: Week 48

  2. Percentage of Subjects and Time to Experiencing a Relapse After Previously Achieving Remission in the Study

    Time frame: Week 48

  3. Percentage of Participants With BVAS of 0 at Week 4

    Time frame: Week 4

  4. In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), Change from baseline in Estimated glomerular filtration rate (eGFR)

    Time frame: Baseline, Week 24 and Week 48

  5. In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), Change from baseline in Urinary albumin:creatinine ratio (UACR)

    Time frame: Baseline, Week 4, 24 and 48

  6. Glucocorticoid-induced Toxicity as Measured by Change From Baseline in the GTI

    Time frame: Baseline, Week 24 and 48

  7. Cumulative dose of glucocorticoids

    Time frame: Week 24 and 48

  8. Change from baseline in the Vasculitis Damage Index (VDI)

    Time frame: Baseline, Week 24 and 48

  9. Change From Baseline in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36

    Time frame: Baseline, Week 24 and 48

07

Study locations

1 of 65 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Sep 11, 2025
StartActual
Nov 10, 2025
Primary completionEst.
Apr 16, 2027
CompletionEst.
Feb 29, 2028
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07168161
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Nov 10, 2025
Primary completion
Apr 16, 2027 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Aug 13, 2026

Study contacts

Aiping Sun
Contact
sunaiping@staidson.com
+86 010-67519614
Minghui Zhao, M.D.
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BDB001

Start the discussion